Algae strain developed and modified by Synthetic Genomics more than doubled oil production Additional research and testing required before commercial application Results published in peer-reviewed journal Nature Biotechnology IRVING, Texas and LA JOLLA, Calif. – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an […]
Customized suite to support Phase 1 study of Advaxis’ personalized cancer immunotherapy SAN DIEGO, June 1, 2017 — Synthetic Genomics, Inc. and Advaxis, Inc. (NASDAQ:ADXS) announced today that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite […]
The first fully automated machine to convert digital code into functional biologics without human intervention creates entirely new avenues for precision medicine SAN DIEGO, May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds […]
LA JOLLA, Calif. – Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production. ExxonMobil and Synthetic Genomics have been jointly researching and developing oil from algae for […]
SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble […]
SAN DIEGO, Jan. 5, 2017 – Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific […]
LA JOLLA, Calif. – November 22, 2016 – Synthetic Genomics, Inc., announced today that Oliver Fetzer, Ph.D., chief executive officer, will present at two upcoming conferences.
LA JOLLA, Calif. – November 9, 2016 – Synthetic Genomics, Inc., announced today that it has appointed industry veterans Tina Nova, Ph.D., and William McKee to its board of directors.
Optimized system has potential to replace the workhorse E. coli by increasing speed and efficiency of protein production and cloning LA JOLLA, CA – August 29, 2016 – Researchers from Synthetic Genomics, Inc. (SGI) announced today the development and extensive engineering of Vibrio natriegens into a next-generation biotechnology host organism Vmax™. Looking to accelerate the […]
(LA JOLLA, CA)—August 4, 2016—Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, Inc. (SGI) have published research describing a method for engineering Mycoplasma mycoides 16S ribosomal RNA (rRNA) using a one-step process that combines CRISPR/Cas9 gene editing system with yeast recombination machinery. The rRNAs are some of the most conserved genes in […]